The first nine months of 2025 have ticked all the boxes at Ipsen. ✅ Strong growth ✅ Expanded pipeline ✅ Clear purpose Hear what David Loew has to say about it.
Ipsen
Fabrication de produits pharmaceutiques
Paris, Île-de-France 282 610 abonnés
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Paris, Île-de-France
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
-
James Frey
GLOBAL PHARMACEUTICALS | Go-To-Market Strategy ~ Brand Development ~ New Product Launch ~ Partnerships & Alliances
-
Frederic Rivart
Consultant IT et Cyber Sécurité
-
Jean-Marc Issa
Head of End User Operations and Services
-
Josep Catlla
Executive Vice President & Chief Corporate Affairs Officer
Nouvelles
-
Press Release: Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance. Learn more: https://lnkd.in/dn8P87-C
-
-
Press Release: Ipsen has entered into an agreement to acquire ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. This will expand our oncology pipeline with a focus on a clinical-stage program in acute myeloid leukemia, an aggressive blood cancer that affects older adults. Learn more: https://lnkd.in/d6ncQ9TY
-
-
You spend your days making life better for patients. We spend ours making life better for you. Medical coverage that actually covers. Time off that honors real life. Financial planning that sees your whole future. Because the people developing tomorrow's treatments deserve more than yesterday's benefits. At Ipsen, employee care isn't a policy. It's a promise. 💙 Learn more about what we offer: https://lnkd.in/eAqcCRCW
-
Cancer has a Plan B. So do we. The MAPK pathway is a vital communication system in our cells. And a common pathway in cancer. Current treatments target specific proteins in the pathway. But it often reactivates. Why? The pathway isn't one protein. It's a chain. Block one point, the signal can reroute or become resistant to treatment. At Ipsen, we're exploring multi-point inhibition. Blocking different proteins across different tumor types. More precision. More tools for oncologists. Better outcomes for tough-to-treat cancers. Swipe. 👉
-
At #ESMO25, we’re spotlighting the power of collaboration. Together with the Global Cancer Coalitions Network, we’re exploring practical ways to improve shared decision making for people living with cancer.
-
Neuroendocrine tumors (NETs) are a group of uncommon tumors that develop in the cells of the neuroendocrine system throughout the body. They account for around 20% of all lung cancer cases yet remain under-recognized and often difficult to detect. For Melanie, this lack of awareness had a profound impact. Her story highlights the complexity of NETs and how every journey is unique. With no two experiences alike, Melanie had to become an expert in her own disease by learning, adapting and finding ways to live well despite the uncertainty. Find out more about Melanie’s story here → https://lnkd.in/eiGvZaFE #LivingwithNETs
-
Ipsen announced data to be presented at ESMO 2025 demonstrating the breadth and depth of Ipsen’s growing portfolio and pipeline. Get the full story → https://lnkd.in/dAX5Nuw7 #ESMO25 #Ipsen #oncology
-
-
Sustainability isn’t a side project here. 🌱 Here’s how our four pillars come to life across Ipsen: 1️⃣ Environment: cleaner operations, smarter energy. 2️⃣ Patients: listening first, then building better research and access. 3️⃣ People: careers that matter, cultures that include. 4️⃣ Governance: do what’s right, report it clearly. Dive into the full report → www.ipsen.com/annualreport
Pages similaires
Parcourir les offres d’emploi
Financement
Ipsen
2 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Dette après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
545 588 264,00 $US